Skip to content

A randomized, double-blind, placebo-parallel-controlled, multicenter clinical trial reevaluating the efficacy and safety of Qiye Shenan dropping pill in the treatment of insomnia (qi deficiency syndrome)

A randomized, double-blind, placebo-parallel-controlled, multicenter clinical trial reevaluating the efficacy and safety of Qiye Shenan dropping pill in the treatment of insomnia (qi deficiency syndrome)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004546
Enrollment
Unknown
Registered
2020-12-23
Start date
2021-03-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anhypnosis

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of insomnia; 2. Patients who meet the diagnostic criteria of insomnia (Qi deficiency syndrome) in TCM; 3. Aged 45-75 years; 4. The cumulative score of 7 components of Pittsburgh sleep quality index was 5; 5. The subjects with informed consent were voluntary and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Shift workers; 2. Subjects with secondary insomnia (insomnia related to other mental disorders, sleep disorders caused by medical diseases (insomnia), sleep disorders caused by substances (insomnia), environmental sleep disorders, etc.; 3. Patients with other sleep disorders: obstructive sleep apnea syndrome (OSAS), restless legs syndrome; 4. The score of Hamilton Depression Scale (HAMD) was more than 17, and the score of Hamilton Anxiety Scale (HAMA) was more than 14; 5. The subjects who use other traditional Chinese medicine or Chinese patent medicine or non short acting sedative hypnotics, antidepressants and anxiolytics to treat insomnia within one week; or the subjects who are receiving dual antiplatelet therapy or monoclonal antiplatelet therapy and are prone to bleeding; 6. Pregnant women and lactating women; 7. Patients with severe primary heart, liver, kidney, blood or other serious diseases affecting their survival have abnormal liver and kidney functions, ALT and AST >= 1.5 times of the upper limit of normal value, Cr > the upper limit of normal value; 8. Subjects with suspected or history of alcohol or drug abuse; 9. Subjects with allergic constitution, such as being allergic to two or more drugs or foods; 10. Subjects known to be allergic to drug components; 11. Subjects who participated in clinical trials of other drugs in recent 3 months.

Design outcomes

Primary

MeasureTime frame
Pittsburgh and sleep quality Index score;Fatigue Severity Scale Score (FSS);

Secondary

MeasureTime frame
ISI score for insomnia severity index;

Countries

Chian

Contacts

Public ContactZhang Jie

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

zhangjie131@sina.com+86 13911122929

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026